Reply to M. K. Kirkwood et al

Affiliations

¹ Ya-Chen Tina Shih, PhD, and Bumyang Kim, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, and Michael T. Halpern, MD, PhD, National Cancer Institute, Bethesda, MD.

Comment

Ya-Chen Tina Shih et al. JCO Oncol Pract. 2021 May.

. 2021 May;17(5):296-297.

doi: 10.1200/OP.21.00176.

¹ Ya-Chen Tina Shih, PhD, and Bumyang Kim, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, and Michael T. Halpern, MD, PhD, National Cancer Institute, Bethesda, MD.

No abstract available

Conflict of interest statement

Ya-Chen Tina ShihConsulting or Advisory Role: Pfizer, AstraZenecaResearch Funding: NovartisNo other potential conflicts of interest were reported.

State of Physician and Pharmacist Oncology Workforce in the United States in 2019.
Shih YT, Kim B, Halpern MT. Shih YT, et al. JCO Oncol Pract. 2021 Jan;17(1):e1-e10. doi: 10.1200/OP.20.00600. Epub 2020 Dec 3. JCO Oncol Pract. 2021. PMID: 33270520 Free PMC article.
ASCO's Selection of Oncologist Workforce Data Source.
Kirkwood MK, Bruinooge SS, Levit LA, Schenkel C, Kosty MP, Pickard T, Ramaekers RC, Williams SF. Kirkwood MK, et al. JCO Oncol Pract. 2021 May;17(5):295-296. doi: 10.1200/OP.21.00081. JCO Oncol Pract. 2021. PMID: 33974814 No abstract available.